Researchers from the Stanford University School of Medicine have reportedly used CRISPR, a gene-editing tool, to repair the gene that causes sickle cell disease. The team is planning the 1st human clinical trial using this technique to correct cells with sickle cell disease, according to Reuters.
“What we’ve finally shown is that we can do it. It’s not just on the chalkboard,” senior author Dr. Matthew Porteus told the news outlet. “We think we have a complete data set to present to the FDA to say we’ve done all pre-clinical experiments to show this is ready for a clinical trial.”